TheJakartaPost
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Popular Reads
Top Results
No results found. Please check your search term and try again
Can't find what you're looking for?
View all search results
Popular Reads
Top Results
No results found. Please check your search term and try again
Can't find what you're looking for?
View all search resultsJapan's new daily COVID-19 cases drop to 6-week low below 100,000
While numbers for Mondays are typically lower than for other days due to reduced testing on the weekend, the last time the nationwide tally was below six digits was on July 19.
Change text size
Gift Premium Articles
to Anyone
Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!
A woman protects herself from the sun with an umbrella during a heatwave as she crosses the street in Tokyo's Shibuya district on August 4, 2019.
(AFP/Charly TRIBALLEAU )
Japan's daily coronavirus tally totaled 95,916 cases on Monday, falling below 100,000 for the first time in six weeks.
While numbers for Mondays are typically lower than for other days due to reduced testing on the weekend, the last time the nationwide tally was below six digits was on July 19.
Tokyo accounted for 9,880 of the cases, falling below 10,000 for the first time since July 11. The capital's seven-day rolling average of new infections stood at 18,800.9 per day, down 24 percent from the previous week.
Among other prefectures, Fukuoka logged 5,729 cases, while Saitama reported 5,419.
Across Japan, patients with severe symptoms rose by one from the previous day to 628, the health ministry said.
A ministry panel approved Monday the use of US pharmaceutical giant Pfizer Inc.'s COVID-19 booster shots for children aged 5 to 11, the first for the age group in Japan.
The panel also granted special fast-track approval for the manufacturing and sale of Evusheld, a COVID-19 antibody drug by Britain's AstraZeneca Plc.
